T-DXd vs hormone therapy for HER2-low advanced breast cancer
Part of Cancer, Hormones & metabolism clinical trials.
This trial compares a targeted antibody-drug conjugate called T-DXd against standard hormone therapy for women with HR+, HER2-low advanced breast cancer that has progressed after first-line endocrine therapy plus a CDK4/6 inhibitor. It aims to see if T-DXd works better than continuing hormone therapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your advanced breast cancer is hormone receptor-positive (HR+) and HER2-low.
- You have already tried a first-line endocrine therapy combined with a CDK4/6 inhibitor (like palbociclib, ribociclib, or abemaciclib), and your cancer got worse.
- You have not had T-DXd or a similar antibody-drug conjugate before.
- You can provide a tumor tissue sample for testing.
- You are a woman aged 19 or older with good enough organ function and performance status (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called T-DXd in people with advanced non-squamous lung cancer that has a specific HER2 gene change (mutation) and has spread to the brain but isn't causing symptoms. The goal is to see if the drug can shrink tumors and help control the cancer.
This trial compares two treatments for advanced breast cancer that is HR-positive, HER2-low or ultralow, and a non-luminal subtype. It tests if a targeted antibody-drug conjugate (T-DXd) works better than the usual first-line therapy combining a CDK4/6 inhibitor with hormone therapy. This study is for people who have not had any treatment for advanced disease.
This trial is studying a drug called T-DXd (trastuzumab deruxtecan) for Chinese women with advanced breast cancer that has a certain protein (HER2) either in high or low amounts. It aims to see how well the drug works in real-world settings.
This trial tests a drug called T-DXd (a targeted chemotherapy) combined with hormone therapy for people with HER2-positive and hormone receptor-positive advanced breast cancer who have not had prior treatment for their metastatic disease. It includes an upfront phase, a maintenance phase, and a retreatment phase to see if restarting T-DXd is effective.
This trial tests a combination of two drugs, T-DXd (a targeted therapy) and an immunotherapy, before surgery for people with early-stage breast cancer that has low levels of HER2 and is hormone receptor positive. The goal is to see if this treatment can shrink the tumor or eliminate cancer cells before surgery.
This study tests a new combination treatment for metastatic breast cancer that is HER2-positive or HER2-low and has stopped responding to T-DXd. The combination includes T-DXd plus a new drug that targets RAGE. The goal is to see if this combination can shrink tumors or slow their growth.
Hear when a new Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.